文献速递免疫规划

中国女性与男性接种四价人乳头瘤病毒疫苗后抗HPV免疫应答持久性评价:随访长达3.5年

Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up.
PubMed 文献 · Vaccine · 2018-02-07

该研究为随机双盲安慰剂对照免疫原性与安全性研究的延伸研究,纳入600名受试者中的468名,在中国9-45岁女性与9-15岁男性中于约42个月(约3.5年)随访检测抗HPV 6/11/16/18抗体。女性中HPV 6、11、16型采用cLIA与IgG LIA检测的血清阳性比例均保持较高,HPV 18型IgG LIA血清阳性率为82.0%、cLIA降至53.6%;男性中所有qHPV型别两种检测的血清阳性率在第42个月均保持较高。结论为3剂qHPV疫苗方案在接种后至少3.5年内诱导持久应答。

要点

  • 女性接种qHPV疫苗后约42个月,HPV 6、11、16型cLIA与IgG LIA血清阳性比例均高。
  • 女性HPV 18型IgG LIA血清阳性率82.0%,cLIA降至53.6%。
  • 男性所有qHPV型别第42个月cLIA与IgG LIA血清阳性率均保持较高。

核心结论

  • 3剂qHPV疫苗接种在中国受试者中诱导针对HPV 6、11、16、18型的持久应答,至少持续至接种后3.5年。

研究设计与样本

  • 本研究为在中国9-45岁女性与9-15岁男性中开展的随机双盲安慰剂对照免疫原性与安全性研究的延伸研究。
  • 基础研究纳入600名受试者,其中468名同意参加延伸研究,于约第42个月(约接种后3.5年)随访。
  • 采用竞争性Luminex免疫分析法(cLIA)与总IgG Luminex免疫分析法(IgG LIA)检测抗HPV 6、11、16、18型抗体。

主要发现

  • 接受qHPV疫苗的女性中,HPV 6、11、16型在首剂接种后约42个月内采用cLIA与IgG LIA检测的血清阳性比例均保持较高。
  • 女性HPV 18型IgG LIA血清阳性率保持高达82.0%,而cLIA降至53.6%,与其他研究观察结果相似。
  • 男性受试者中所有qHPV型别在第42个月采用cLIA与IgG LIA检测的血清阳性率均保持较高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This was an extension study of a randomized, double-blind, placebo-controlled immunogenicity and safety study of the quadrivalent human papillomavirus (qHPV) (HPV 6, 11, 16, and 18) vaccine conducted in Chinese female subjects aged 9-45 years and male subjects aged 9-15 years. To investigate the persistence of anti-HPV 6, -11, -16, and -18 responses among Chinese subjects, subjects enrolled in the base study were followed up at around month 42 (approximately 3.5 years after vaccination). METHODS: Among 600 subjects enrolled in the base study, a total of 468 subjects consented for participation in the extension study. Anti-HPV 6, -11, -16, and -18 antibodies were detected by the competitive Luminex immunoassay (cLIA) and total IgG Luminex immunoassay (IgG LIA). RESULTS: Among the female subjects who received the qHPV vaccine, the proportions of subjects remained seropositive were high with both the cLIA and IgG LIA for HPV type 6, 11, and 16 through approximately 42 months following the first dose vaccination. For HPV 18, the seropositivity rate remained high as 82.0% with the IgG LIA, while it decreased to 53.6% with the cLIA, which was similar to the findings observed in other studies. The seropositivity rates remained high at month 42 for all qHPV types with both the cLIA and IgG LIA among the male subjects. CONCLUSIONS: Administration of a 3-dose regimen of qHPV vaccine induces durable anti-HPV 6, anti-HPV 11, anti-HPV 16, and anti-HPV 18 responses among Chinese subjects for at least 3.5 years after vaccination. ClinicalTrials.gov registry:NCT01427777.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Huang T, Liu Y, Li Y, et al. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up. Vaccine. 2018. PMID: 29428178. doi:10.1016/j.vaccine.2018.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。